Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

I-FP-CIT SPECT enables the detection of presynaptic dopaminergic denervation. It allows to differentiate degenerative parkinsonian syndromes from secondary parkinsonian syndromes or essential tremor, and patients with suspected dementia with Lewy bodies from those with other dementia subtypes. The aim of our study was to evaluate the appropriateness of I-FP-CIT SPECT prescriptions, identify prescriber profiles and analyze changes in prescriptions over a decade in the Neurology department of Avicenne University hospital. This retrospective study included all patients who underwent I-FP-CIT SPECT between February 2009 and May 2019 (n = 723). Clinical and paraclinical data were compared between three groups based on the relevance of I-FP-CIT SPECT prescription: "inappropriate", "uncertain" and "relevant". We showed that inappropriate indications accounted for 37.5% of I-FP-CIT SPECT requests. Hospital neurologists and neurologists with mixed practice accounted for 74.1% of I-FP-CIT SPECT requests, hospital movement disorders specialists being more likely to prescribe appropriately (67.1%) than hospital non-movement disorders specialists (33.3%). Following the replacement of the neuro-oncology team with a team including movement disorders specialists, the percentage of relevant SPECT 123I-FP-CIT prescriptions rose from 37.5% to 81.0%. These observations suggest that seeking the expertise of a movement disorders specialist would be more relevant than the systematic prescription of I-FP-CIT SPECT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500384PMC
http://dx.doi.org/10.1038/s41598-024-73777-yDOI Listing

Publication Analysis

Top Keywords

i-fp-cit spect
32
parkinsonian syndromes
12
movement disorders
12
disorders specialists
12
spect
9
relevance i-fp-cit
8
spect prescriptions
8
spect requests
8
requests hospital
8
i-fp-cit
7

Similar Publications

Rapid eye movement (REM) sleep behavior disorder (RBD) is a frequent non-motor symptom of Parkinson's disease (PD) and a potential early marker of synucleinopathy-related neurodegeneration. While striatal dopaminergic dysfunction in PD-RBD has been extensively studied, the role of extrastriatal monoaminergic alterations -particularly those involving serotonin - remains poorly understood. In this study, 155 PD patients underwent [I]FP-CIT SPECT imaging to assess striatal and extrastriatal tracer binding, reflecting dopaminergic and broader monoaminergic function, respectively.

View Article and Find Full Text PDF

Further delineation of LRSAM1-related Charcot-Marie-Tooth type 2P with parkinsonism.

Eur J Med Genet

July 2025

Département de Neurologie, Hôpital Central, CHRU Nancy, 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France; Centre de référence des Pathologies Neuromusculaires Nord/Est/Ile de France, CHRU Nancy, 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France.

LRSAM1 pathogenic variations are linked to an axonal motor and sensory polyneuropathy known as Charcot-Marie-Tooth disease type 2P, but extra peripheral neurologic impairment is suspected. We report a patient with CMT2P and parkinsonism. We describe a 66-year-old man presenting with pes cavus, gait instability, and mild distal motor weakness.

View Article and Find Full Text PDF

Diagnostic Value of Swallow Tail Sign at Brain MRI in Patients with Clinically Uncertain Parkinsonian Syndrome.

Radiology

July 2025

NIHR Nottingham Biomedical Research Centre, Mental Health & Clinical Neurosciences, Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Derby Rd, Nottingham NG7 2UH, United Kingdom.

Background Striatal dopaminergic deficits, established with iodine 123-2β-carbomethoxy-3β-(4-iodophenyl)--(3-fluoropropyl)-nortropan (I-FP-CIT) SPECT, support the diagnosis of Parkinson disease (PD) or atypical parkinsonian syndrome in clinical uncertainty. The swallow tail sign (STS) at susceptibility-weighted (SW) MRI helps differentiate patients with PD from controls, but its utility in clinically uncertain parkinsonian syndromes remains unclear. Purpose To compare the diagnostic performance of STS absence at SW MRI in diagnosing PD with that of I-FP-CIT SPECT in participants with clinically uncertain parkinsonian syndrome.

View Article and Find Full Text PDF

Background: In some patients with parkinsonism and abnormal dopamine transporter (DAT) imaging using [I]FP-CIT single-photon emission computed tomography (SPECT), subsequent clinical evolution does not fit well with a neurodegenerative diagnosis.

Objective: The objective was to analyze the results of positron emission tomography (PET) with the recently developed DAT radioligand [F]FE-PE2I in patients with persistent diagnostic uncertainty despite an abnormal previous [I]FP-CIT SPECT scan.

Methods: This retrospective study included 19 patients with suspected parkinsonism and persistent diagnostic uncertainty after visually abnormal [I]FP-CIT SPECT who subsequently underwent [F]FE-PE2I PET (time between the two scans: 3.

View Article and Find Full Text PDF

Dopamine transporter (DAT) is closely associated with neurodegenerative diseases such as Parkinson's disease (PD). To develop an in vivo stable radioligand targeting DAT, we synthesized a novel iodine-131-labeled tropane analog [I]1 with deuteration on both the N-fluoropropyl and 2β-carbomethoxy positions of the tropane scaffold and then biologically compared with the previously reported analog [I]FP-CIT-d with deuteration only on the N-fluoropropyl group. The radioligand [I]1 was obtained via a radioiodine-destannylation reaction with a radiochemical yield of ~95%, a radiochemical purity of > 99% and a molar activity of 12.

View Article and Find Full Text PDF